Galectins as modulators of tumor progression in head and neck squamous cell carcinomas.
Head and neck squamous cell carcinomas (HNSCCs) remain a significant cause of morbidity worldwide. Biological therapies able to induce and/or upregulate antitumor immune responses could represent a complementary approach to conventional treatments for patients with HNSCC because, despite advances in surgery, radiotherapy, and chemotherapy, the overall survival rates for these patients have not changed over recent decades. Galectins are involved in the control of cell proliferation, cell death, and cell migration and in the modulation of various functions of the immune system. In this context, galectin-1 is known to protect HNSCCs from the immune system. The present review details the involvement of galectins in HNSCC biology and suggests a number of approaches to reduce the levels of expression of galectin-1 in HNSCCs, with the aim of improving the efficiency of HNSCC immunotherapy.
Saussez
Sven
S
Laboratory of Histology, Faculty of Medicine and Pharmacy, University of Mons-Hainaut, Belgium.
Camby
Isabelle
I
Toubeau
Gerard
G
Kiss
Robert
R
D002294:Carcinoma, Squamous Cell / Q000453:epidemiology / Q000235:genetics / Q000276:immunology / Q000503:physiopathology* / Q000601:surgery; D002465:Cell Movement / Q000502:physiology; D018450:Disease Progression; D037483:Galectin 1 / Q000378:metabolism / Q000502:physiology*; D037502:Galectin 3 / Q000378:metabolism; D037161:Galectins / Q000378:metabolism / Q000502:physiology*; D006258:Head and Neck Neoplasms / Q000453:epidemiology / Q000235:genetics / Q000276:immunology / Q000503:physiopathology*; D006801:Humans; D007150:Immunohistochemistry; D011379:Prognosis; D013601:T-Lymphocytes / Q000502:physiology
D037483:Galectin 1; D037502:Galectin 3; D037161:Galectins; C092525:LGALS7 protein, human